Postnatal bone marrow houses mesenchymal progenitor cells that are osteoblast precursors. These cells have established therapeutic potential, but they are difficult to maintain and expand in vitro, presumably because little is known about the mechanisms controlling their fate decisions. To investigate the potential role of Notch signaling in osteoblastogenesis, we used conditional alleles to genetically remove components of the Notch signaling system during skeletal development. We found that disruption of Notch signaling in the limb skeletogenic mesenchyme markedly increased trabecular bone mass in adolescent mice. Notably, mesenchymal progenitors were undetectable in the bone marrow of mice with high bone mass. As a result, these mice developed severe osteopenia as they aged. Moreover, Notch signaling seemed to inhibit osteoblast differentiation through Hes or Hey proteins, which diminished Runx2 transcriptional activity via physical interaction. These results support a model wherein Notch signaling in bone marrow normally acts to maintain a pool of mesenchymal progenitors by suppressing osteoblast differentiation. Thus, mesenchymal progenitors may be expanded in vitro by activating the Notch pathway, whereas bone formation in vivo may be enhanced by transiently suppressing this pathway.
Notch signaling mediates communication between neighboring cells to control cell fate decisions during embryogenesis 1 and in postnatal life 2 . In the canonical Notch pathway, the single-pass transmembrane cell surface receptors (Notch 1-4 in mammals) undergo two sequential proteolytic cleavages upon binding of its ligands (Jagged-1 and Jagged-2 and Delta-like-1, Delta-like-3 and Delta-like-4 in mammals) presented on a neighboring cell surface 3 . As a result, the Notch intracellular domain (NICD) is released from the plasma membrane and translocates to the nucleus, where it interacts with a transcription factor of the CSL family (RBP-Jk or CBF-1 in mammals) to activate transcription of target genes 4 . The transmembrane domain cleavage and release of NICD is mediated by the g-secretase complex, which in mammals contains either presenilin-1 or presenilin-2 as the catalytic subunit 5 ; removal of both presenilin-1 (encoded by Psen1) and presenilin-2 (encoded by Psen2) completely abolishes NICD production 6, 7 .
Clear genetic evidence showing a direct role for Notch signaling in the skeleton has been elusive. Mouse mutants lacking individual receptors [8] [9] [10] [11] , most ligands [12] [13] [14] [15] [16] or Psen2 (ref. 7) either die in utero before skeletogenesis or show no overt skeletal phenotype. Although mice lacking the genes encoding either Delta-like-3 (ref. 17) or presenilin-1 (refs. 18,19) show defects in the axial skeleton, a direct effect on skeletal development has been difficult to discern owing to the early deficiency in somite segmentation and maintenance. Finally, mice lacking Psen1 and Psen2 in the limb mesenchyme are missing certain phalanges, but it has not been clear whether the phenotype is a direct consequence of losing Notch signaling in skeletogenic cells 20 . Here we set out to test the hypothesis that Notch signaling directly regulates skeletal development.
RESULTS
Removal of c-secretase in limb mesenchyme affects long bones As a first step to examine the role of Notch signaling in skeleton formation, we systematically analyzed the bones of mice in which Psen2 was globally deleted and Psen1 was selectively removed from the skeletogenic mesenchyme in the limb and the calvaria by using Prx1-Cre (Prx1-Cre; Psen1 f/f Psen2 -/-, hereafter PPS mutants) 20, 21 . The PPS mice were born at the expected mendelian ratio and appeared normal except for variable digit anomalies 20 , but all died between 9 and 10 weeks of age. The reason(s) for premature death is (are) not clear at present, but the mice showed severe ulcerative dermatitis in the ventral cervical area, possibly reflecting excessive inflammatory response.
Morphological analyses of the skeleton revealed a striking phenotype in mutant mice at 8 weeks of age. X-ray radiography indicated that PPS mutant mice not only had shorter long bones when compared with littermate controls (Psen2 -/-, which had no obvious phenotype), but also showed a marked increase in radiodensity within the bone marrow cavity (Fig. 1a) . Three-dimensional reconstruction of the tibia using micro computed tomography (mCT) confirmed that a massive accumulation of bone occluded much of the presumptive marrow cavity in the mutant mice (Fig. 1b) . In addition, the radiolucent growth plate cartilage was greatly elongated in the mutant mice (Fig. 1b) . Histology of longitudinal sections through the medial portion of the tibia further showed that PPS mutants contained excessive cancellous bone encapsulating a prominent wedge-shaped extension of the growth plate cartilage (Fig. 1c,d ). In the most severe case, the mutant diaphysis appeared to be entirely filled with cancellous bone, with no recognizable marrow cavity or clear demarcation of cortical bone (Fig. 1e) . Similarly, the secondary ossification center of the PPS mutant also contained excessive bone and no obvious marrow (Fig. 1f) . Examination at a higher magnification indicated that the cartilage extension was chiefly due to accumulation of hypertrophic chondrocytes ( Fig. 1f-h ), whereas the length of the nonhypertrophic region appeared unchanged (Fig. 1f) . Notably, the calvarium, also targeted by Prx1-Cre, was not affected in the PPS mutant, a result confirmed by both X-ray radiography (data not shown) and histology ( Supplementary Fig. 1 online) . Thus, removal of Psen1 and Psen2 results in expansion of the hypertrophic cartilage and an excess of trabecular bone in endochondral bones, but not in calvaria, of 8-week-old mice.
Deletion of Notch1 and Notch2 resembles removal of c-secretase The skeletal malformations caused by the removal of g-secretase prompted us to determine whether abrogation of Notch signaling was solely responsible for this phenotype. To this end, we used the same strategy to remove Notch1 and Notch2 from the early limb mesenchyme. Prx1-Cre; Notch1 -/f Notch2 f/f mice (hereafter PNN mutants) were born at the expected mendelian ratio and showed a skeletal phenotype strikingly similar to that of PPS mutants. In particular, X-ray radiography revealed that at 8 weeks of age the PNN mutants had notably shorter long bones and markedly higher radiodensity within the trabecular bone region when compared to wild-type (Notch1 f/f Notch2 f/f ) littermates (Fig. 2a) . Tibia mCT analyses confirmed both elongation of the radiolucent growth plate cartilage and increase of bone mass within the marrow cavity of PNN mutants (Fig. 2b) . Finally, histology of the tibia revealed excessive trabecular bone encasing a wedge-shaped extension of the growth plate cartilage and a notable reduction of the marrow space in both primary and secondary ossification centers of PNN mutants (Fig. 2c) . As seen in PPS mice, cartilage elongation in PNN mice was due to expansion of the hypertrophic zone, with no apparent increase in the non-hypertrophic region (Fig. 2d) . Of note, the increase in bone mass appeared to be limited to the trabecular region; although the organization of the cortical bone seemed to be altered, no significant changes in cortical thickness were observed between mutant and wild-type littermates at this stage (Fig. 2d) . Overall, PNN mutants show a postnatal skeletal phenotype qualitatively identical to that of PPS mutants.
The similarities between the PPS and the PNN mice indicated that loss of Notch signaling was responsible for the bone phenotypes in both settings and prompted us to analyze the PNN mice in further detail. We first explored the cellular basis for the high-bone-mass phenotype. Staining for tartrate-resistant acid phosphatase (TRAP) activity on tibia sections of mice at 8 weeks of age revealed that the mutant mice in fact had more osteoclasts per bone surface area than wild-type littermates (Fig. 2e,f) . The percentage of bone surfaces eroded by osteoclasts was also higher in the PNN mice (Fig. 2f) . However, calcein double-labeling experiments indicated that whereas the mineral apposition rate as indicated by the distance between the double labels was not significantly altered in either the trabecular or the cortical bone, the PNN mutants showed a marked increase in the number of double-labeled surfaces within the trabecular bone (Fig. 2g) . Indeed, cuboidal (active) osteoblasts normalized to areas of trabecular bone on sections were greatly increased in the mutant mice, although the number of flat (inactive) osteoblasts did not change (Fig. 2h) , and the osteoblast density (osteoblast number normalized to trabecular bone perimeter) was not altered (data not shown). Thus, the increase of bone mass in PNN mice was not due to defects in osteoclasts or upregulation of osteoblast activity, but rather to an increase in the total number of active osteoblasts.
To investigate whether Notch signaling is required in committed osteoblasts, we attempted to ablate Notch1 and Notch2 using Col1-Cre, which expresses Cre under the control of a 2.3-kilobase promoter sequence of the mouse Col1a1 gene and was previously shown to function effectively in these cells 22 Fig. 2a-f online) . Western blot analyses revealed that Notch1 (490%), but not Notch2 (B20%), was efficiently deleted in the long bones of C1NN mutants at 8 weeks of age ( Supplementary  Fig. 2g ). Thus, we cannot rule out the possibility that the lack of bone phenotype at this age may be due to incomplete deletion of Notch2.
Notch signaling regulates embryonic skeletal development
We next determined whether Notch removal affects the embryonic skeleton. At embryonic day 18.5 (E18.5), histology revealed that both PPS ( Supplementary Fig. 3 online) and PNN embryos ( Fig. 3a) contained elongated hypertrophic cartilage and excessive osteoblasts within the marrow region. Notably, embryos with one Notch1 allele remaining (Prx1-Cre; Notch1 f/+ Notch2 f/f ) showed similar phenotypes to PNN mutants, but those with one Notch2 allele remaining (Prx1-Cre; Notch1 f/f Notch2 f/+ ) had relatively normal bone marrow and only a slight elongation of the hypertrophic zone ( Fig. 3a) , indicating that Notch2 is probably the predominant regulator in the endochondral skeleton. The larger osteoblast population in both PPS (Supplementary Fig. 3 ) and PNN embryos expressed high amounts of bone sialoprotein (encoded by Ibsp; Fig. 3b ), as well as type 1 collagen (encoded by Col1a1) and alkaline phosphatase (encoded by Akp2; data not shown). Of note, the number of osteoclasts expressing TRAP (encoded by Acp5) also increased within the trabecular region of PNN mutant mice (Fig. 3b) . The excessive number of trabecular osteoblasts in PNN mutants did not reflect changes in cell proliferation, as BrdU labeling experiments revealed a B20% reduction in the labeling index when mutant trabecular osteoblasts were compared to the wild type (n ¼ 3, P ¼ 0.05). Similarly, immunohistochemistry with an antibody specific for activated caspase-3 detected no difference in apoptosis of trabecular osteoblasts between mutant and wild-type mice (data not shown). Thus, genetic disruption of Notch signaling from the limb mesenchyme results in elongation of the hypertrophic cartilage and overproduction of trabecular osteoblasts in embryonic long bones.
To further characterize the cartilage defect, we performed molecular analyses on sections of embryonic tibia. At E18.5, the hypertrophic zone expressing type X collagen (encoded by Col10a1) was significantly longer in PPS ( Supplementary Fig. 3 ) and PNN mutants than in wild-type littermates (Fig. 3b) . Indian hedgehog (encoded by Ihh), normally restricted to the prehypertrophic and early hypertrophic regions at this stage, persisted at a lower level throughout much of the mutant hypertrophic zone (Fig. 3b) . Matrix metallopeptidase-13 (encoded by Mmp13), normally expressed at high levels in a single row of terminal hypertrophic chondrocytes at the chondro-osseous junction, was activated in the mutant mouse at a lower level in many rows of hypertrophic cells before eventually reaching the higher level (Fig. 3b) . The delayed progression toward terminal hypertrophy (Mmp13-positive) may have contributed to the overall lengthening of the hypertrophic zone. In addition, in vivo BrdU labeling experiments revealed that the proliferation rate of growth plate chondrocytes was reduced by B25% in PNN mutants versus wild-type littermates (n ¼ 3, P ¼ 0.004). At E14.5, both histological staining and the expression profile of Col10a1 indicated that the hypertrophic region was substantially shortened in PNN mutants (Fig. 3c) . The two major Ihh-expressing domains were less well separated, and the number of terminal hypotrophic chondrocytes expressing Mmp13 was markedly reduced in PNN mutants (Fig. 3c) . Thus, Notch signaling in the growth plate positively controls the proliferation of nonhypertrophic chondrocytes, the onset of chondrocyte hypertrophy and also subsequent progression toward terminal hypertrophy.
Notch regulation of bone marrow mesenchymal progenitors
The results so far indicate that Notch removal enhances osteoblast differentiation from precursors. We reasoned that unchecked differentiation might lead to a deficit in bone marrow mesenchymal progenitors (including both mesenchymal stem cells and the more committed cell types, such as osteoblast progenitors). Because these cells are found in the clonogenic subset of adherent bone marrow stromal cells (BMSCs), known as colony-forming unit fibroblasts (CFU-Fs) 23, 24 , we cultured BMSCs to assay for the frequency of CFUFs in the bone marrow of 8-week-old mice. Strikingly, although a similar number of total marrow cells was retrieved from PNN mutant and wild-type bones, the mutant marrow contained hardly any 'type 1' (see Methods) CFU-Fs (0 or 1 per 1 Â 10 6 marrow cells), whereas wild-type samples typically contained B300 per 1 Â 10 6 marrow cells (Fig. 4a) . In addition, the mutant samples formed markedly fewer (B5 per 1 Â 10 6 marrow cells) and smaller (fewer cells within each cluster, data not shown) 'type 2' CFU-Fs than the wildtype samples (B20 per 1 Â 10 6 marrow cells). Thus, removal of Notch signaling from the limb mesenchyme severely reduces the number of bone marrow mesenchymal progenitors in adolescent mice.
A decrease in mesenchymal progenitors would predict reduced differentiation capacity for the PNN BMSCs. To examine whether this is the case, we further cultured the BMSCs in osteogenic media after formation of CFU-Fs and found that the PNN cells produced far fewer osteoblast-lineage cells (alkaline phosphatase (AP)-positive) than did wild-type cells (Fig. 4b) . In addition, when BMSCs from 8-or 15-week-old mice were cultured at a high density (see Methods) in either osteogenic or regular medium, the PNN samples were markedly impaired in osteoblast differentiation, as indicated by the low AP activity (Fig. 4c) , as well as the low mRNA levels for several common osteoblast markers (Fig. 4d) . Similarly, when BMSCs were cultured in an adipogenic medium, the PNN cells produced virtually no adipocytes identifiable by the characteristic lipid droplets (Fig. 4e) , even though Notch signaling was previously shown to be dispensable for adipocyte differentiation 25 . These results are therefore consistent with a severe deficit in bone marrow mesenchymal progenitors in PNN mice.
To corroborate further that Notch controls the fate of bone marrow mesenchymal progenitors, we examined whether DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a g-secretase inhibitor that blocks all Notch signaling, alters the frequency of CFU-Fs among wild-type BMSCs. DAPT completely eliminated type 1 CFU-Fs (Fig. 4f) , although it did not alter the number of type 2 CFU-Fs (B20 per 1 Â 10 6 marrow cells). Of note, when assayed directly for AP activity without being further cultured in osteogenic conditions, nearly all type 2 CFU-Fs from the DAPT-treated samples stained strongly positively, with many containing only AP-positive cells, whereas in the control samples the clusters contained only a small number of positive cells (Fig. 4g,h) . Thus, Notch signaling (inhibited by DAPT) negatively regulates osteoblastogenesis, and this finding further supports the conclusion that the lack of osteoblast differentiation from the PNN cultures (Fig. 4b) was most probably due to the loss of precursors, instead of deficiency in the osteogenic program per se. Overall, these results support the notion that Notch signaling normally maintains mesenchymal progenitors while suppressing osteoblast differentiation.
Progressive bone loss in mature PNN mice
The severe reduction in the number of mesenchymal progenitors in adolescent mice, along with the increased osteoclast numbers and total activity, predict that PNN mice may show a net loss of bone when they age. To test this possibility, we took advantage of the fact that the PNN mice did not die prematurely (unlike PPS mice in this regard) and examined the long bones by X-ray and mCT techniques at progressively older ages. Because the increase in trabecular bone mass at 8 weeks was most noticeable at the metaphyseal region (immediately below the growth plate) (Fig. 2b) , we focused our analyses on this region in the older mice. Strikingly, although the PNN mice still maintained a slightly higher trabecular bone mass than controls at 13 weeks of age (data not shown), the magnitude was markedly reduced when compared to that at 8 weeks. Moreover, at 14 and 15 weeks of age, the mutant mice became progressively more osteopenic, and at 26 weeks they reached a normalized bone mass that was only 10% that of the control (Fig. 5a and Supplementary Table 1 online), indicating that the PNN mice rapidly lost bone mass as they aged. The age-related bone phenotype was observed in both male and female mice. In agreement with the mCT data showing a rapid decrease in trabeculae number (Supplementary Table 1 ), histology of bone sections confirmed a marked reduction of bone trabeculae at the metaphyseal region in 26-weekold PNN mice compared to control mice (Fig. 5b) . Furthermore, the osteoblast density on trabecular bone surfaces was significantly reduced in the mutant at this age (cuboidal osteoblast density down by 15% and flat osteoblast density down by 40%, P o 0.05), indicating a marked decrease in the total number of trabecular osteoblasts in the aged PNN mice. In addition, the elongated region of hypertrophic cartilage, characteristic of the PNN mice in the embryo and at 8 weeks of age ( Fig. 3a and Fig. 2c , respectively), was no longer present at 26 weeks. Instead, the growth plate of the PNN mice was notably shorter and disorganized and had considerably fewer chondrocytes than that of normal mice (Fig. 5b) . The shortening of the hypertrophic region indicates that the increased total osteoclast activity in the mutant mice eventually overtook the accumulation of hypertrophic cartilage at the older age. Overall, the data indicate that sustaining a proper pool of mesenchymal progenitors through Notch signaling is crucial for bone homeostasis in adult life and that Notch signaling is also required for maintaining a normal growth plate.
Mechanisms for Notch function in bone
Because the PNN mice formed more osteoclasts even though Prx1-Cre did not target this lineage, we hypothesized that Notch-deficient osteoblasts may affect osteoclastogenesis. Because osteoblasts are known to balance osteoclastogenesis through production of the positive regulator RANKL (encoded by Tnfsf11) and the antagonist osteoprotegerin (encoded by Tnfrsf11b) 26 , we examined mRNA levels in the tibiae of 8-week-old mice by real-time PCR. Western blot analyses confirmed that Notch2 (both the full-length and the NICD forms) abundance was reduced by 490% in the long bones of PNN mice, although Notch1 NICD abundance was reduced by only B60% (Fig. 6a) . The Notch1 antibody did not detect a distinct full-length protein in either wild-type or PNN bones in this experiment (data not shown). Of note, the PNN tibia mRNA showed a 480% reduction in osteoprotegerin expression, but it had a 100% increase in RANKL expression (Fig. 6b) . Consequently, the RANKL/osteoprotegerin ratio was one order of magnitude higher than it was in normal osteoblasts, explaining the increased osteoclast number in the mutant mice. Thus, Notch signaling in long-bone osteoblasts indirectly regulates osteoclast differentiation by controlling the expression of RANKL and osteoprotegerin. This finding is consistent with our recent in vitro studies in which removal of Notch signaling in osteoblasts enhanced osteoclastogenesis from bone marrow macrophage progenitors in coculture experiments 27 . Moreover, although the C1NN mice did not show a notable bone phenotype at 8 weeks of age, they showed a loss of trabecular bone mass at 5 months, owing to an increase in total osteoclast activities (data not shown). However, because C1NN mice maintained a relatively normal population of bone marrow mesenchymal progenitors (data not shown), their age-dependent osteopenic phenotype was notably less severe than that in PNN mice. Overall, these results support the notion that Notch not only controls osteoblastogenesis early in the lineage, but also acts in more mature osteoblast-lineage cells to regulate osteoclastogenesis indirectly.
To probe the molecular mechanism through which Notch maintains mesenchymal progenitors, we examined the expression of the Hes and Hey family of molecules, known mediators of canonical Notch signaling in other tissues. Of the six potential targets of Notch, Hes1, Hes5, Hes7, Hey1, Hey2 and HeyL (ref. 28 ), Hey1 and HeyL expression was found to be markedly downregulated in the long bones of PNN mice at 8 weeks of age (Fig. 6b) , whereas Hes1 expression was not changed, and expression of the others was not detected at any substantial levels (o0.01% of GAPDH expression; data not shown). Similarly, BMSCs from 15-week-old mice expressed only Hes1, Hey1 and HeyL at considerable levels, and expression of all three was markedly lower in the PNN samples (Fig. 6c) . These results therefore identify Hes1, Hey1 and HeyL as potential mediators of Notch signaling in osteoblast-lineage cells.
We next examined whether Notch controls osteoblast differentiation by affecting Runx2 and osterix (the latter encoded by Sp7), two crucial transcription activators of this lineage. We first determined whether expression of the genes encoding Runx2, osterix or both was increased in the long bones of 8-week-old PNN mice. Real-time PCR assays showed that both genes were, contrary to our expectations, downregulated in the mutant bones containing a higher bone mass (Fig. 6b) , indicating that changes in Runx2 and osterix abundance are probably not the primary mechanism through which Notch suppresses osteoblast differentiation. To test whether Notch signaling can inhibit the transactivating ability of Runx2, we performed transient transfection assays. In comparison to cells expressing Runx2 alone, coexpression of either NICD1 (from Notch1), NICD2 (from Notch2), Hes1 or Hey1 significantly reduced the expression of a Runx2-responsive reporter in both CHO cells (Fig. 6d-f) , and the mouse bone marrow stromal cell line ST2 ( Supplementary Fig. 4 online and data not shown). To understand further the regulation of Runx2 activity by Hes and Hey proteins, we performed deletion studies, using Hey1 as a representative example. In transfection experiments, Hey1 deletion mutants missing either the helix-loop-helix (Hey1-DHLH) or the Orange domain (Hey1-DORG) did not repress Runx2 activity and instead enhanced it (Fig. 6f) , indicating that these constructs may have a dominant-negative effect. In contrast, Hey1-DC, which lacks a C-terminal portion of Hey1, retained some but not all of the inhibitory function on Runx2 (Fig. 6f) . Thus, the HLH and Orange domains are crucial for the inhibition of Runx2, whereas the C-terminal region may also play a part. Overall, Notch signaling may inhibit osteoblast differentiation through Hes and Hey proteins that impede the function of Runx2.
To determine whether Hes and Hey proteins physically associate with Runx2, we performed co-immunoprecipitation experiments. ST2 cells were transfected to overexpress Hey1 or its variant (all Myctagged) either alone or with Runx2; the cell lysates were immunoprecipitated with an antibody to Runx2 and then probed with an antibody to Myc after SDS-PAGE. The full-length Hey1 protein was detected in the Runx2 immunoprecipitate in similar amounts regardless of Runx2 overexpression (Fig. 6g) , indicating that Hey1 interacts with endogenous Runx2 and is likely to be the limiting factor in the interaction. Consistent with the transfection data that the HLH and Orange domains are crucial for the inhibition effect of Hey1 on Runx2, neither Hey1-DHLH nor Hey1-DORG interacted with Runx2 (Fig. 6g) . In contrast, Hey1-DC retained the interaction with Runx2 (Fig. 6g) . The stronger Runx2 signal detected with Hey1-DC was probably due to the fact that Hey1-DC was expressed at much higher amounts than wild-type Hey1 in these experiments (Fig. 6g, bottom) . Similarly to Hey1-DC, Hes1-DC interacted with Runx2 with or without Runx2 overexpression (Fig. 6g) . Thus, Hes and Hey proteins physically interact with Runx2 in the cell through the HLH and Orange domains.
Finally, we confirmed that Notch signaling was indeed activated in the osteoblast lineage. In transgenic Notch reporter mice that express GFP under the control of repeated RBP-Jk response elements 29 , we have consistently observed GFP-positive cells in live bone fragments free of marrow cells (data not shown). To specifically monitor Notch1 lineages, we took advantage of the Notch1::Cre mouse that allows Cre recombination specifically in cells that have experienced Notch1 activation 30 . In mice carrying both Notch1::Cre and the Rosa26-LacZ reporter (R26R) 31 , LacZ-positive cells were found both on the trabecular bone surface and within the bone matrix ( Supplementary Fig. 5a online) . Notably, none of the growth plate chondrocytes were LacZ-positive, indicating either that Notch1 is not activated in the chondrocyte lineage, or that the level of activation was below the sensitivity threshold of this approach, as previously discussed 30 . If the former is true, the chondrocyte phenotype in PNN mice could be due to either loss of Notch2 signaling in chondrocytes or potential non-cell-autonomous effects caused by loss of signaling by Notch1, Notch2 or both in other cell types; future studies are necessary to discern which of these possibilities is true. Furthermore, a subset of BMSCs from the Notch1::Cre-R26R mice expressed LacZ, indicative of active or previous Notch1 signaling in these cells ( Supplementary Fig. 5b,c) .
DISCUSSION
In summary, the present study demonstrates that Notch signaling in osteoblast-lineage cells performs crucial functions for bone homeostasis. First, it maintains bone marrow mesenchymal progenitors through inhibition of osteoblast differentiation. Second, it regulates osteoclastogenesis from bone marrow macrophage precursors by modulating the production of RANKL and osteoprotegerin by osteoblasts. On the one hand, in our model, Notch deficiency leads to excessive osteoblastogenesis and, therefore, more bone and fewer bone marrow mesenchymal progenitors in adolescent mice. On the other hand, in older mice, diminution of the progenitor pool causes a deficit in osteoblast production, which, when combined with heightened osteoclast differentiation, leads to precipitous bone loss associated with age. The model is consistent with our finding that the total number of trabecular osteoblasts in the PNN mice was greater than that in control mice at a young age (increased bone surface but no change in osteoblast density on surface), but was reduced to below the control level when the mice grew older (decreased bone surface and decreased osteoblast density). However, it should be noted that our methodology does not allow direct assessment of mesenchymal progenitors and their differentiation in vivo. Thus, the exact relationship between the progenitors and the age-related osteopenic phenotype remains to be further elucidated.
The finding that Notch inhibits osteoblastogenesis is consistent with a number of in vitro studies 32-34 but seems to be at odds with several others that suggest a stimulatory role 35, 36 . As most of these in vitro studies relied on overexpression of either NICD or the ligands, the discrepancy may be caused by differences in the level and/or the duration of Notch activation achieved in each study. In addition, because the stimulatory effect of Notch was observed only in cells treated with bone morphogenic protein 35, 36 , Notch may have enhanced proliferation of bone morphogenic protein-induced osteoblasts without affecting differentiation per se in those studies.
We concur with previous findings that Hes and Hey family molecules may mediate Notch inhibition of osteoblast differentiation through inhibition of Runx2 activity. Whereas a previous study identified Hey1 and Hey2 as potential mediators in aortic valves 37 , we find that Hes1, Hey1 and HeyL are probable candidates in bone marrow mesenchymal progenitors. In keeping with previous reports that Hey1 inhibited the transcriptional activity of Runx2 in both COS7 cells 37 and cultured osteoblastic cells 38 , we show that both Hes1 and Hey1 inhibit Runx2 in CHO and ST2 cells. Moreover, the inhibition by Hey1 requires its HLH and Orange domains, both of which are also necessary for the physical interaction between Hey1 and Runx2 in the cell. A definitive answer to the role of Hes and Hey proteins in osteoblastogenesis will require analyses of compound mutant mice.
Our study indicates that a short pulse of Notch inhibitor treatment may enhance bone formation by stimulating osteoblastogenesis from bone marrow mesenchymal progenitors in vivo. However, both this study and our other data 27 indicate that sustained inhibition of Notch signaling in osteoblasts leads to overproduction of osteoclasts and bone resorption. Finally, activating Notch signaling in bone marrow mesenchymal progenitors may help to maintain their phenotype and to expand their population in vitro. Analyses of mice. We obtained radiographs of mouse hindlimbs with a Faxitron X-ray system (Faxitron X-ray), and used mCT (mCT 40, Scanco Medical) for three-dimensional reconstruction and quantification of bone parameters. For Figure 5a , we reconstructed each image from 100 16-mm slices immediately below the growth plate, with a threshold of 200. For postnatal samples, we performed histology on paraffin sections after decalcification. For dynamic histomorphometry of postnatal mice, we injected calcein (Sigma) intraperitoneally at 7.5 mg/kg on days 7 and 2 before killing and then sectioned tibiae in methyl-methacrylate. We performed in situ hybridization and BrdU labeling as previously described 43 , and we performed quantitative histomorphometry on paraffin sections using the Osteomeasure Analysis System (Osteometrics).
Cell cultures and in vitro assays. We harvested bone marrow cells and performed high-density cultures as previously described 44 . For CFU-F assays, we seeded single-cell suspensions of 3 Â 10 6 nucleated bone marrow cells on T25 flasks and cultured the cells in DMEM (Sigma) containing 20% lot-selected FBS (Hyclone) and 1-thioglycerol (Sigma) for 11-14 d without change of medium. For CFU-F assays, we scored colonies with more than 50 small, round or spindle-shaped cells in direct contact with each other as type 1 CFU-Fs and counted clusters with more than 100 cells including large cells with multiple processes as type 2 CFU-Fs. We induced differentiation of BMSCs by either osteogenic (50 mg/ml ascorbic acid, 50 mM bglycerol-2-phosphate) or adipogenic (0.5 mM 3-isobutyl-1-methylxanthine, 60 mM indomethacine, 0.5 mM hydrocortisone) DMEM containing 10% FBS (Atlas).
We extracted bone proteins from tibiae and femora after bone marrow cells were flushed away. The antibody to Notch1 was previously described 45 and the antibody to Notch2 (C651.6DbHN) was from the Developmental Studies Hybridoma Bank at the University of Iowa.
We extracted total RNA with TRIzol (Invitrogen) either from bone fragments after they had been flushed to remove marrow cells or from cultured BMSCs. We performed real-time PCR with SYBR-Green (BioRad) in an ABI-7500 machine (Applied Biosystems).
We performed transient transfections with Lipofectamine (Invitrogen). For luciferase assays, we seeded ST2 and CHO cells in 24-well plates at 3 Â 10 4 and 4.5 Â 10 4 cells, respectively, and cotransfected the NICD-, Hes1-or Hey1-expressing constructs or the corresponding empty vectors (0.13 mg) along with pCMV-Runx2 (0.07 mg, gift of R. Civitelli), p6OSE2-Luc (0.1 mg, gift of R. Civitelli) and pRL-Renilla (0.01 mg, Promega) for 8 h using Lipofectamine (0.5 ml/well), before further culturing the cells for 48 h and finally harvesting them for dual luciferase activity assays (Promega). The NICD1-or NICD2-expressing construct was previously descibed 46 . pSV2-CMV-Hes1 was originally from R. Kageyama. We generated pCS2-Hey1, pCS2-Hey1-DHLH, pCS2-Hey1-DORG, pCS2-Hey1-DC and pCS2-Hes1-DC by cloning the appropriate cDNAs into the pCS2+MT vector (containing a 6Â Myc tag). We generated cDNAs encoding the truncated proteins by PCR from full-length mouse cDNA clones (American Type Culture collection): Hes1-DC, deletion of Hes1 amino acids (aa) 161-282; Hey1-DC, deletion of Hey1 aa 177-299; Hey1-DHLH, deletion of Hey1 aa 66-107; Hey1-DORG, deletion of Hey1 aa 121-166. For co-immunoprecipitation experiments, we transiently transfected ST2 cells with the Hes1 or Hey1 constructs in combination with pCMV-Runx2 or the empty vector; we immunoprecipitated the cell lysate with an antibody to Runx2 (Santa Cruz Biotechnology) and resolved the precipitate by SDS-PAGE before probing the membrane with an antibody to Myc (Santa Cruz Biotechnology). The antibody to GAPDH is from Chemicon.
Statistical analyses. Statistical analyses were performed using the Student's t-test.
Note: Supplementary information is available on the Nature Medicine website.
